Added to YB: 2026-01-29
Pitch date: 2026-01-27
QURE [bullish]
uniQure N.V.
+1.5%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Market Cap
$1.4B
Pitch Price
$24.04
Price Target
40.75 (+67%)
Dividend
N/A
EV/EBITDA
-8.03
P/E
-5.01
EV/Sales
75.69
Sector
Biotechnology
Category
special_situation
The Market Overreaction Creating a Biotech Multibagger - UniQure N.V.
QURE: Gene therapy for Huntington's disease crashed 75% on FDA reversal but regulatory momentum rebuilding. AMT-130 showed 75% slowing disease progression vs natural history at 36mo. Late-Jan FDA Type A meeting may clarify renewed Accelerated Approval path. Risk-weighted upside ~61% to $40.75 target.
Read full article (7 min)